Cargando…
Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical manage...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401116/ https://www.ncbi.nlm.nih.gov/pubmed/36001553 http://dx.doi.org/10.1371/journal.pone.0272648 |
_version_ | 1784772897908195328 |
---|---|
author | Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel S. Moore-Hepburn, Charlotte Drouin, Olivier Papenburg, Jesse Salvadori, Marina I. Laffin, Melanie Kakkar, Fatima Morris, Shaun K. |
author_facet | Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel S. Moore-Hepburn, Charlotte Drouin, Olivier Papenburg, Jesse Salvadori, Marina I. Laffin, Melanie Kakkar, Fatima Morris, Shaun K. |
author_sort | Piché-Renaud, Pierre-Philippe |
collection | PubMed |
description | BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. METHODS: This is a national, prospective study of infants with SARS-CoV-2 from April 8(th) 2020 to May 31(st) 2021 using the infrastructure of the Canadian Paediatric Surveillance Program. Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection from both inpatients and outpatients seen in clinics and emergency departments were included. Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization. RESULTS: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions (aOR = 4.53, 2.06–9.97), and infants <1 month had higher odds of hospitalization then infants aged 1–3 months (aOR = 3.78, 1.97–7.26). In total, 20 infants (3.8%) met criteria for severe disease. CONCLUSIONS: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group was found to be uncommon. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants. |
format | Online Article Text |
id | pubmed-9401116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94011162022-08-25 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel S. Moore-Hepburn, Charlotte Drouin, Olivier Papenburg, Jesse Salvadori, Marina I. Laffin, Melanie Kakkar, Fatima Morris, Shaun K. PLoS One Research Article BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. METHODS: This is a national, prospective study of infants with SARS-CoV-2 from April 8(th) 2020 to May 31(st) 2021 using the infrastructure of the Canadian Paediatric Surveillance Program. Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection from both inpatients and outpatients seen in clinics and emergency departments were included. Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization. RESULTS: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions (aOR = 4.53, 2.06–9.97), and infants <1 month had higher odds of hospitalization then infants aged 1–3 months (aOR = 3.78, 1.97–7.26). In total, 20 infants (3.8%) met criteria for severe disease. CONCLUSIONS: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group was found to be uncommon. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants. Public Library of Science 2022-08-24 /pmc/articles/PMC9401116/ /pubmed/36001553 http://dx.doi.org/10.1371/journal.pone.0272648 Text en © 2022 Piché-Renaud et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel S. Moore-Hepburn, Charlotte Drouin, Olivier Papenburg, Jesse Salvadori, Marina I. Laffin, Melanie Kakkar, Fatima Morris, Shaun K. Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title | Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_full | Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_fullStr | Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_full_unstemmed | Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_short | Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_sort | clinical manifestations and disease severity of sars-cov-2 infection among infants in canada |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401116/ https://www.ncbi.nlm.nih.gov/pubmed/36001553 http://dx.doi.org/10.1371/journal.pone.0272648 |
work_keys_str_mv | AT picherenaudpierrephilippe clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT panettaluc clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT farrardaniels clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT moorehepburncharlotte clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT drouinolivier clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT papenburgjesse clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT salvadorimarinai clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT laffinmelanie clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT kakkarfatima clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT morrisshaunk clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada |